Nigar Shireen, Shimosato Takeshi
Department of Nutrition and Food Technology, Jashore University of Science and Technology, Jashore, Bangladesh.
Department of Biomolecular Innovation, Institute for Biomedical Sciences, Shinshu University, Nagano, Japan.
Front Nutr. 2019 Aug 27;6:140. doi: 10.3389/fnut.2019.00140. eCollection 2019.
Unmethylated cytosine-guanine dinucleotide (CpG) motifs are potent stimulators of the host immune response. Cellular recognition of CpG motifs occurs via Toll-like receptor 9 (TLR9), which normally activates immune responses to pathogen-associated molecular patterns (PAMPs) indicative of infection. Oligodeoxynucleotides (ODNs) containing unmethylated CpGs mimic the immunostimulatory activity of viral/microbial DNA. Synthetic ODNs harboring CpG motifs resembling those identified in viral/microbial DNA trigger an identical response, such that these immunomodulatory ODNs have therapeutic potential. CpG DNA has been investigated as an agent for the management of malignancy, asthma, allergy, and contagious diseases, and as an adjuvant in immunotherapy. In this review, we discuss the potential synergy between synthetic ODNs and other synthetic molecules and their immunomodulatory effects. We also summarize the different synthetic molecules that function as immune modulators and outline the phenomenon of TLR-mediated immune responses. We previously reported a novel synthetic ODN that acts synergistically with other synthetic molecules (including CpG ODNs, the synthetic triacylated lipopeptide PamCSK, lipopolysaccharide, and zymosan) that could serve as an immune therapy. Additionally, several clinical trials have evaluated the use of CpG ODNs with other immune factors such as granulocyte-macrophage colony-stimulating factor, cytokines, and both endosomal and cell-surface TLR ligands as adjuvants for the augmentation of vaccine activity. Furthermore, we discuss the structural recognition of ODNs by TLRs and the mechanism of functional modulation of TLRs in the context of the potential application of ODNs as wide-spectrum therapeutic agents.
未甲基化的胞嘧啶-鸟嘌呤二核苷酸(CpG)基序是宿主免疫反应的强效刺激剂。细胞通过Toll样受体9(TLR9)识别CpG基序,TLR9通常会激活针对指示感染的病原体相关分子模式(PAMP)的免疫反应。含有未甲基化CpG的寡脱氧核苷酸(ODN)模拟病毒/微生物DNA的免疫刺激活性。携带与病毒/微生物DNA中鉴定出的基序相似的CpG基序的合成ODN会引发相同的反应,因此这些免疫调节性ODN具有治疗潜力。CpG DNA已被研究作为治疗恶性肿瘤、哮喘、过敏和传染病的药物,以及免疫治疗中的佐剂。在本综述中,我们讨论了合成ODN与其他合成分子之间的潜在协同作用及其免疫调节作用。我们还总结了作为免疫调节剂起作用的不同合成分子,并概述了TLR介导的免疫反应现象。我们之前报道了一种新型合成ODN,它与其他合成分子(包括CpG ODN、合成的三酰化脂肽PamCSK、脂多糖和酵母聚糖)协同作用,可作为一种免疫疗法。此外,一些临床试验评估了将CpG ODN与其他免疫因子(如粒细胞-巨噬细胞集落刺激因子、细胞因子以及内体和细胞表面TLR配体)联合使用作为增强疫苗活性的佐剂的效果。此外,我们在ODN作为广谱治疗剂的潜在应用背景下,讨论了TLR对ODN的结构识别以及TLR功能调节的机制。